Joseph S. McCracken - Nov 16, 2022 Form 4 Insider Report for LUMOS PHARMA, INC. (LUMO)

Role
Director
Signature
/s/ Ryan Trytten, attorney-in-fact
Stock symbol
LUMO
Transactions as of
Nov 16, 2022
Transactions value $
$20,120
Form type
4
Date filed
11/18/2022, 03:31 PM
Previous filing
Aug 26, 2022
Next filing
Dec 15, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LUMO Common Stock Purchase $20.1K +4K +34.13% $5.03 15.7K Nov 16, 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.005 to $5.0536, inclusive. The reporting person undertakes to provide to the issuer, any security holder of issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the ranges set forth in this footnote to this Form 4.
F2 Includes 237 restricted stock units ("RSUs") previously reported as holdings of the Reporting Person granted under the Issuer's 2009 Equity Incentive Plan (the "Plan"). The RSUs will vest, and shares will be delivered to the Reporting Person in a single installment on April 3, 2023, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.